Related Experiment Video
Updated: Sep 22, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
Irena Wieleba1, Kamila Wojas-Krawczyk2, Izabela Chmielewska2
1Pneumonology, Oncology and Allergology Department, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland. i.m.wieleba@gmail.com.
Abstract:
Lung adenocarcinoma predominates among diagnosed nonsmall cell lung cancer subtypes in nonsmokers. The introduction of immune checkpoint inhibitors into clinical practice offered patients prolonged progression-free survival and overall survival times. However, the results demonstrate that the benefits do not apply to all patients. Nivolumab is a monoclonal antibody against the PD-1 protein expressed mainly on T lymphocytes and is widely used in cancer therapy in different settings. Tumor cells often express the PD-L1 molecule and can effectively block the action of PD-1-positive lymphocytes. A body of knowledge regarding the high expression of PD-L1 on tumor cells highlights that it does not always correlate with the effectiveness of anti-PD-1 therapy. The side effects of the therapy also constitute a significant issue. These side effects can occur at any time during anti-PD-1 treatment and lead to discontinuation and even the death of the patient. In these situations, it is possible to delay the dosage. Nevertheless, unfortunately, it is not possible to reduce the dose of anti-PD-1 antibody, which would undoubtedly minimize side effects, leaving the patient's immune system active. In our preliminary study, we analyzed the effect of different concentrations of nivolumab on the functioning of T lymphocytes. Activation and proliferation markers were investigated on T cells after being cultured with antigen-stimulated autologous dendritic cells. This process may indicate an appropriate concentration of nivolumab, which shows clinical activity with minimal side effects.
Insights
This study explores optimal nivolumab concentrations for T-cell function in non-small cell lung cancer, aiming to enhance anti-PD-1 therapy effectiveness while minimizing side effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Lung adenocarcinoma is a common non-small cell lung cancer subtype in nonsmokers.
- Immune checkpoint inhibitors like nivolumab improve survival but benefit all patients.
- PD-L1 expression on tumors doesn't always predict anti-PD-1 therapy response, and side effects are a concern.
Purpose of the Study:
- To investigate the impact of varying nivolumab concentrations on T lymphocyte function.
- To identify a nivolumab dosage that balances clinical activity with reduced side effects.
Main Methods:
- Culturing T cells with antigen-stimulated autologous dendritic cells.
- Analyzing T cell activation and proliferation markers at different nivolumab concentrations.
Main Results:
- Preliminary data analyzed the effect of different nivolumab concentrations on T lymphocyte functioning.
- Investigated activation and proliferation markers on T cells after co-culture with dendritic cells.
Conclusions:
- Determining optimal nivolumab concentrations may improve anti-PD-1 therapy efficacy.
- This approach could lead to better management of side effects in lung cancer patients.
